美股异动丨莫德纳盘前大涨超11%，Q3营收及EPS均胜于预期

Core Viewpoint - Moderna's stock surged over 11% in pre-market trading following the release of its third-quarter earnings report, despite a significant year-over-year revenue decline [1] Financial Performance - Revenue for the third quarter was reported at $1.02 billion, a 45% decrease compared to the previous year, but it exceeded analyst expectations of $879.6 million [1] - Sales from COVID-19 vaccines reached $971 million during the quarter, which included $781 million in sales from the U.S. and $190 million from international markets [1] - The company recorded a net loss of $200 million, translating to a loss of $0.51 per share, which was significantly better than the analyst forecast of a loss of $2.11 per share [1]